Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections

References

• EdelsbergJWeyckerDBarronRPrevalence of antibiotic resistance in US hospitalsDiagn Microbiol Infect Dis20147825526224360267
   PubMed Web of Science ®Google Scholar
• Oritavancin (orbactiv) for skin and skin structure infectionsMed Lett Drugs Ther2015573525555072
   PubMed Web of Science ®Google Scholar
• ORBACTIV™ (Oritavancin) For InjectionParsippany, NJThe Medicines Company2014 Prescribing Information
   Google Scholar
• ZhanelGGSchweizerFKarlowskyJAOritavancin: mechanism of actionClin Infect Dis201254Suppl 3S214S21922431851
   PubMed Web of Science ®Google Scholar
• GrovesPSearleMSMackayJPWilliamsDHThe structure of an asymmetric dimer relevant to the mode of action of the glycopeptide antibioticsStructure199427477547994574
   PubMed Web of Science ®Google Scholar
• AllenNENicasTIMechanism of action of oritavancin and related glycopeptide antibioticsFEMS Microbiol Rev20032651153212586393
   PubMed Web of Science ®Google Scholar
• BelleyANeesham-GrenonEMcKayGOritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitroAntimicrob Agents Chemother20095391892519104027
   PubMed Web of Science ®Google Scholar
• BelleyANeesham-GrenonEArhinFFMcKayGAParrTRJrMoeckGAssessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureusAntimicrob Agents Chemother2008523820382218644953
   PubMed Web of Science ®Google Scholar
• BelleyAMcKayGAArhinFFOritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killingAntimicrob Agents Chemother2010545369537120876372
   PubMed Web of Science ®Google Scholar
• BaquirBLemaireSVan BambekeFTulkensPMLinLSpellbergBMacrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancinClin Infect Dis201254Suppl 3S229S23222431853
   PubMed Web of Science ®Google Scholar
• CitronDMKwokYYApplemanMDIn vitro activity of oritavancin (ly333328), vancomycin, clindamycin, and metronidazole against Clostridium perfringens, Propionibacterium acnes, and anaerobic gram-positive cocciAnaerobe200511939516701537
   PubMed Web of Science ®Google Scholar
• MendesREFarrellDJSaderHSFlammRKJonesRNActivity of oritavancin against gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010–2013)J Antimicrob Chemother20157049850425362568
   PubMed Web of Science ®Google Scholar
• KarlowskyJAWalktyAJBaxterMRAdamHJZhanelGGIn vitro activity of oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013Diagn Microbiol Infect Dis20148031131525294303
   PubMed Web of Science ®Google Scholar
• ArhinFFSarmientoIBelleyAEffect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testingAntimicrob Agents Chemother2008521597160318299406
   PubMed Web of Science ®Google Scholar
• PattiGJKimSJYuTYVancomycin and oritavancin have different modes of action in enterococcus faeciumJ Mol Biol20093921178119119576226
   PubMed Web of Science ®Google Scholar
• ArthurMDepardieuFReynoldsPCourvalinPModerate-level resistance to glycopeptide ly333328 mediated by genes of the VanA and VanB clusters in enterococciAntimicrob Agents Chemother1999431875188010428906
   PubMed Web of Science ®Google Scholar
• RubinoCMVan WartSABhavnaniSMAmbrosePGMcCollamJSForrestAOritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremiaAntimicrob Agents Chemother2009534422442819635952
   PubMed Web of Science ®Google Scholar
• AmbrosePGDrusanoGLCraigWAIn vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humansClin Infect Dis201254Suppl 3S220S22822431852
   PubMed Web of Science ®Google Scholar
• BhavnaniSMOwenJSLoutitJSPorterSBAmbrosePGPharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjectsDiagn Microbiol Infect Dis2004509510215474317
   PubMed Web of Science ®Google Scholar
• FetterlyGJOngCMBhavnaniSMPharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram doseAntimicrob Agents Chemother20054914815215616289
   PubMed Web of Science ®Google Scholar
• BoylanCJCampanaleKIversenPWPhillipsDLZeckelMLParrTRJrPharmacodynamics of oritavancin (ly333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionAntimicrob Agents Chemother2003471700170612709343
   PubMed Web of Science ®Google Scholar
• RuppMEFeyPDLongoGMEffect of ly333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection modelJ Antimicrob Chemother20014770570711328790
   PubMed Web of Science ®Google Scholar
• KaatzGWSeoSMAeschlimannJRHoulihanHHMercierRCRybakMJEfficacy of ly333328 against experimental methicillin-resistant Staphylococcus aureus endocarditisAntimicrob Agents Chemother1998429819839559828
   PubMed Web of Science ®Google Scholar
• Saleh-MghirALefortAPetegniefYActivity and diffusion of ly333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalisAntimicrob Agents Chemother1999431151209869575
   PubMed Web of Science ®Google Scholar
• LefortASaleh-MghirAGarryLCarbonCFantinBActivity of ly333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalisAntimicrob Agents Chemother2000443017302111036016
   PubMed Web of Science ®Google Scholar
• GerberJSmirnovAWellmerAActivity of ly333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillinAntimicrob Agents Chemother2001452169217211408247
   PubMed Web of Science ®Google Scholar
• CabellosCFernàndezAMaiquesJMExperimental study of ly333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitisAntimicrob Agents Chemother2003471907191112760866
   PubMed Web of Science ®Google Scholar
• FreemanJMarquisMCrowtherGSOritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut modelJ Antimicrob Chemother2012672919292622899803
   PubMed Web of Science ®Google Scholar
• HeineHSBassettJMillerLEfficacy of oritavancin in a murine model of bacillus anthracis spore inhalation anthraxAntimicrob Agents Chemother2008523350335718606841
   PubMed Web of Science ®Google Scholar
• AllenNEFrom vancomycin to oritavancin: the discovery and development of a novel lipoglycopeptide antibioticAnti Infect Agents Med Chem201092347
   Google Scholar
• CoreyGRKablerHMehraPSOLO I InvestigatorsSingle-dose oritavancin in the treatment of acute bacterial skin infectionsN Engl J Med20143702180219024897083
   PubMed Web of Science ®Google Scholar
• CoreyGRGoodSJiangHSOLO II InvestigatorsSingle-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority studyClin Infect Dis20156025426225294250
   PubMed Web of Science ®Google Scholar
• TalanDAKrishnadasanAGorwitzRJEMERGEncy ID Net Study GroupComparison of Staphylococcus aureus from skin and soft-tissue infections in us emergency department patients, 2004 and 2008Clin Infect Dis20115314414921690621
   PubMed Web of Science ®Google Scholar
• MoranGJKrishnadasanAGorwitzRJEMERGEncy ID Net Study GroupMethicillin-resistant S. aureus infections among patients in the emergency departmentN Engl J Med200635566667416914702
   PubMed Web of Science ®Google Scholar
• SingerAJTalanDAManagement of skin abscesses in the era of methicillin-resistant Staphylococcus aureusN Engl J Med20143701039104724620867
   PubMed Web of Science ®Google Scholar
• TiceADRehmSJMeeting the challenges of methicillin-resistant Staphylococcus aureus with outpatient parenteral antimicrobial therapyClin Infect Dis201051Suppl 2S171S17520731574
   PubMed Web of Science ®Google Scholar
• TiceAOritavancin: a new opportunity for outpatient therapy of serious infectionsClin Infect Dis201254Suppl 3S239S24322431855
   PubMed Web of Science ®Google Scholar